These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23178634)

  • 1. Updated experience with inolimomab as treatment for corticosteroid-refractory acute graft-versus-host disease.
    García-Cadenas I; Valcárcel D; Martino R; Piñana JL; Novelli S; Esquirol A; Garrido A; Moreno ME; Granell M; Moreno C; Saavedra S; Briones J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):435-9. PubMed ID: 23178634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease.
    Piñana JL; Valcárcel D; Martino R; Moreno ME; Sureda A; Briones J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2006 Nov; 12(11):1135-41. PubMed ID: 17085306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of corticosteroid refractory acute GVHD treated with an Inolimomab-based algorithm: a single center experience.
    Girerd S; Renaud M; Guilhot J; Giraud C; Larchee R; Jollet I; Guilhot F
    Bone Marrow Transplant; 2013 Sep; 48(9):1243-8. PubMed ID: 23503532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies.
    Bay JO; Dhédin N; Goerner M; Vannier JP; Marie-Cardine A; Stamatoullas A; Jouet JP; Yakoub-Agha I; Tabrizi R; Faucher C; Diez-Martin JL; Nunez G; Parody R; Milpied N; Espérou H; Garban F; Galambrun C; Kwiatkovski F; Darlavoix I; Zinaï A; Fischer A; Michallet M; Vernant JP
    Transplantation; 2005 Sep; 80(6):782-8. PubMed ID: 16210965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steroid-refractory acute GVHD: lack of long-term improved survival using new generation anticytokine treatment.
    Xhaard A; Rocha V; Bueno B; de Latour RP; Lenglet J; Petropoulou A; Rodriguez-Otero P; Ribaud P; Porcher R; Socié G; Robin M
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):406-13. PubMed ID: 21736868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination Therapy with Inolimomab and Etanercept for Severe Steroid-Refractory Acute Graft-versus-Host Disease.
    van Groningen LF; Liefferink AM; de Haan AF; Schaap NP; Donnelly JP; Blijlevens NM; van der Velden WJ
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):179-82. PubMed ID: 26386320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute gastrointestinal graft-versus-host disease in pediatric patients: serum albumin on day 5 from initiation of therapy correlates with nonrelapse mortality and overall survival.
    Goussetis E; Paisiou A; Kitra V; Peristeri I; Vessalas G; Stefanaki K; Panayotou I; Giamaiou K; Kontou E; Kitzoni M; Dimopoulou MN; Karkelis S; Kafritsa Y; Rapsomaniki E; Papassotiriou I; Tsirigotis P; Roma E; Graphakos S
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):1058-66. PubMed ID: 21073975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease.
    Gómez-Almaguer D; Ruiz-Argüelles GJ; del Carmen Tarín-Arzaga L; González-Llano O; Gutiérrez-Aguirre H; Cantú-Rodríguez O; Jaime-Pérez J; Carrasco-Yalán A; Giralt S
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):10-5. PubMed ID: 18158956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients.
    Kurtzberg J; Prockop S; Teira P; Bittencourt H; Lewis V; Chan KW; Horn B; Yu L; Talano JA; Nemecek E; Mills CR; Chaudhury S
    Biol Blood Marrow Transplant; 2014 Feb; 20(2):229-35. PubMed ID: 24216185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anti-CD25 monoclonal antibody with antithymocytic globulin for steroid-resistant severe acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation].
    Ye CX; Sun J; Liu QF; Qu H; Xu D; Zhang Y; Meng FY
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Dec; 28(12):2224-6. PubMed ID: 19114364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody.
    Kobbe G; Schneider P; Rohr U; Fenk R; Neumann F; Aivado M; Dietze L; Kronenwett R; Hünerlitürkoglu A; Haas R
    Bone Marrow Transplant; 2001 Jul; 28(1):47-9. PubMed ID: 11498743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
    Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective.
    Schub N; Günther A; Schrauder A; Claviez A; Ehlert C; Gramatzki M; Repp R
    Bone Marrow Transplant; 2011 Jan; 46(1):143-7. PubMed ID: 20348971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease.
    Bordigoni P; Dimicoli S; Clement L; Baumann C; Salmon A; Witz F; Feugier P
    Br J Haematol; 2006 Nov; 135(3):382-5. PubMed ID: 16984386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited benefit of pentostatin salvage therapy for steroid-refractory grade III-IV acute graft-versus-host disease.
    Alam N; Atenafu EG; Tse G; Viswabandya A; Gupta V; Kim D; Lipton JH; Messner HA; Kuruvilla J
    Clin Transplant; 2013; 27(6):930-7. PubMed ID: 24304375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
    Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alemtuzumab for severe steroid-refractory gastrointestinal acute graft-versus-host disease.
    Meunier M; Bulabois CE; Thiebaut-Bertrand A; Itzykson R; Carre M; Carras S; Garban F; Cahn JY
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1451-4. PubMed ID: 24910381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes.
    Uberti JP; Ayash L; Braun T; Reynolds C; Silver S; Ratanatharathorn V
    Bone Marrow Transplant; 2004 Sep; 34(5):425-31. PubMed ID: 15273705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease.
    Dartois C; Freyer G; Michallet M; Hénin E; You B; Darlavoix I; Vermot-Desroches C; Tranchand B; Girard P
    Clin Pharmacokinet; 2007; 46(5):417-32. PubMed ID: 17465640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.